Search

Displaying results 4681 - 4690 of 6949 in total
  1. Drug

    Empasiprubart

    go.drugbank.com/drugs/DB16469
    Investigational

    Empasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    STC3141

    go.drugbank.com/drugs/DB16475
    Investigational

    STC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    STI-1499

    go.drugbank.com/drugs/DB16487
    Investigational

    STI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.

    Categories: Experimental Unapproved Treatments for COVID-19
  4. Drug

    TY027

    go.drugbank.com/drugs/DB16500
    Investigational

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    BCc1

    go.drugbank.com/drugs/DB16504
    Experimental

    BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Fludiazepam

    go.drugbank.com/drugs/DB01567
    IllicitInvestigational

    It is a scheduled drug in the U.S., but is approved for use in Japan.

  7. Drug

    Pecilocin

    go.drugbank.com/drugs/DB13459
    Experimental

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  8. Drug

    Orbifloxacin

    go.drugbank.com/drugs/DB11443
    ExperimentalVet approved

    It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.

  9. Drug

    Ganetespib

    go.drugbank.com/drugs/DB12047
    Investigational

    Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.

  10. Drug

    N-sulfoglucosamine sulfohydrolase recombinant

    go.drugbank.com/drugs/DB12722
    Investigational

    N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).